70639-94-0

Usage

Uses

Used in Organic Synthesis:
1-cyclopentyl-3-(triMethylsilyl)prop-2-yn-1-one is used as a reagent in organic synthesis for the preparation of a wide range of organic compounds. Its unique structure allows for versatile reactions, making it a valuable component in the creation of complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 1-cyclopentyl-3-(triMethylsilyl)prop-2-yn-1-one is utilized as a building block for the development of new drugs. Its incorporation into molecular structures can lead to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Development:
Similarly, in agrochemicals, 1-cyclopentyl-3-(triMethylsilyl)prop-2-yn-1-one serves as a key intermediate in the synthesis of various agrochemical products. Its application aids in the advancement of crop protection agents and other agricultural chemicals.
Used in Research and Development:
1-cyclopentyl-3-(triMethylsilyl)prop-2-yn-1-one is also used as a research tool in the field of organic chemistry. Its distinctive chemical properties make it an important compound for exploring new reaction pathways and understanding the fundamentals of organic reactions.
Used in Fine Chemicals Industry:
In the production of fine chemicals, 1-cyclopentyl-3-(triMethylsilyl)prop-2-yn-1-one is employed as a crucial component. Its presence in the synthesis process contributes to the creation of high-quality specialty chemicals used across various applications.

Upstream product

• 4524-93-0 Cyclopentanecarboxylic acid chloride 
• 14630-40-1 Bis(trimethylsilyl)ethyne 
• 72096-97-0 3-cyclopentyl-1-trimethylsilyl-1,2-propadiene 
• 167303-65-3 N-Cyclopentanecarbonyl-N,O-dimethylhydroxylamine 
• 1066-54-2 trimethylsilylacetylene 
• 3400-45-1 cyclopentanecarboxylic acid 

Downstream Products

• 1508318-89-5 C₂₂H₂₉NO₄Si 
• 1508318-94-2 C₂₂H₂₉NO₄Si 
• 112256-09-4 3-cyclopentyl-1-propyn-3-ol 
• 1508318-88-4 C₂₃H₃₁NO₄Si 
• 1508318-93-1 C₂₃H₃₁NO₄Si 
• 1508318-85-1 (S)-4-benzyl-3-((R)-3-cyclopentyl-3-hydroxy-4-pentynoyl)oxazolidin-2-one 
• 1508319-01-4 (R)-5-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-cyclopentyl-5-(2,6-diethylpyridin-4-yl)-1-oxopentan-3-yl acetate tosylate salt 
• 1508318-98-6 (R)-5-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-cyclopentyl-1-(2,6-diethylpyridin-4-yl)-5-oxopent-1-yn-3-yl acetate 
• 1508318-92-0 C₁₉H₂₁NO₄ 
• 1508318-90-8 C₂₉H₃₄N₂O₄ 
• 1508318-97-5 C₁₉H₂₁NO₄ 
• 749928-78-7 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxybut-1-ynyl]-2-fluoro-phenyl}-2-methyl-propionitrile 
• 749929-84-8 2-[2-chloro-4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)phenyl]-2-methylpropanenitrile 
• 749929-85-9 2-{2-Chloro-4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2-methyl-propionitrile 

Relevant academic research and scientific papers

Gold-Catalyzed Dehydrogenative Cycloisomerization of 1,4-Enyne Esters to 3,5-Disubstituted Phenol Derivatives

A method to prepare synthetically important 3,5-disubstituted phenol derivatives that relies on the sequential gold(I)-catalyzed dehydrogenative cycloisomerization of 1,4-enyne esters in the presence of 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) or N-fluorobenzenesulfonimide (NFSI) is described. The synthetic versatility of the methodology was exemplified by a gram-scale reaction of one example, the ease to realize subsequent functional transformations of an adduct, and the application of the method to the synthesis of the bioactive molecule LUF5771. (Figure presented.).

Synthesis of filibuvir. Part I. Diastereoselective preparation of a β-hydroxy alkynyl oxazolidinone and conversion to a 6,6- disubstituted 2H-pyranone

This is the first in a series of three papers describing the identification and development of a commercial synthesis of filibuvir (1). This contribution describes development of an Evans aldol reaction to control the tertiary alcohol stereocenter, a challenging variant of that strategy in that both reacting partners were nonstandard (acetate enolate and ketone electrophile). A sequence consisting of Sonogashira coupling, acylation and hydrogenation delivered acetate 24, and Dieckmann cyclization provided β-keto lactone 2.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

Compounds of formula (I) are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.